⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2165253 | 0.76 | — | — | |
| SCHEMBL1509437 | 0.73 | — | — | |
| SCHEMBL2785525 | 0.71 | — | — | |
| SCHEMBL632905 | 0.71 | — | — | |
| SCHEMBL22317588 | 0.69 | KDM4E (0.31) | — | |
| SCHEMBL67583 | 0.68 | RAF1 (0.46) | — | |
| SCHEMBL28791608 | 0.68 | — | — | |
| SCHEMBL18838194 | 0.67 | PARP1 (0.42) | — | |
| SCHEMBL13348706 | 0.67 | — | — | |
| SCHEMBL12570340 | 0.67 | ADORA2B (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516008-B1 | NOVEL ANTIVIRAL COMPOUNDS | UNIV LEUVEN KATH (BE) | 2014-04-16 | — | — | EP | disclosed |
| US-20120316161-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-12-13 | — | — | US | disclosed |
| EP-2516008-A1 | NOVEL ANTIVIRAL COMPOUNDS | Katholieke Universiteit Leuven (BE) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076765-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-06-30 | — | — | WO | disclosed |
| EP-1699800-B1 | BICYCLIC HETEROCYCLIC P-38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-02-10 | — | — | EP | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20090264409-A1 | Bicyclic Heterocyclic p-38 Kinase Inhibitors | DONG QING | 2009-10-22 | — | — | US | disclosed |
| US-7569571-B2 | Substituted pyrazolo [3,4-d]pyrimidines as cytokine modulators | NOVARTIS AG (CH) | 2009-08-04 | — | — | US | disclosed |
| US-20070142405-A1 | Such as N-cyclopropyl-4-methyl-3-(4-phenyl-pyrazolo[3,4-d]pyrimidin-1-yl)-benzamide; for inhibiting p38 kinase mediated diseases and disorders such as inflammatory diseases | TRIAD THERAPEUTICS, INC. | 2007-06-21 | — | — | US | disclosed |
| EP-1699800-A2 | BICYCLIC HETEROCYCLIC P-38 KINASE INHIBITORS | Novartis AG (CH) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005063766-A2 | BICYCLIC HETEROCYCLIC P-38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-07-14 | — | — | WO | disclosed |
| US-4345935-A | PREEMERGENT AND POSTEMERGENT APPLICATION | ELI LILLY AND COMPANY (US) | 1982-08-24 | — | — | US | disclosed |